acute coronary syndrome

PTSD and Sleep Disorders Linked to Sharp Rise in Acute Coronary Syndrome Risk

By MedXY 01/27/2026

A comprehensive meta-analysis of over 22 million individuals identifies mental disorders, particularly PTSD and sleep disturbances, as major independent risk factors for acute coronary syndrome, urging a paradigm shift toward integrated cardiovascular and psychiatric care.

Cardiology news

The 30-Day Ischemic Penalty: Why Early Aspirin Withdrawal in ACS Requires Caution

By MedXY 01/03/2026

A landmark analysis from the NEOMINDSET trial demonstrates that while potent P2Y12 inhibitor monotherapy reduces bleeding, it significantly increases ischemic risk in the first 30 days after PCI for acute coronary syndrome, suggesting that the timing of aspirin withdrawal is critical for patient safety.

Cardiology news

JCAD Predicts Adverse Cardiovascular Events in ACS Patients with High Residual Risk

By MedXY 01/03/2026

A breakthrough study identifies the junctional protein associated with coronary artery disease (JCAD) as a significant predictor of recurrent cardiovascular events in ACS patients, particularly those with residual lipid and inflammatory risk, by modulating coagulation and fibrinolysis pathways.

Cardiology Internal Medicine news

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

By MedXY 01/02/2026

Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombotic risk profile, offering a viable strategy for individualized care.

Cardiology Internal Medicine news

Alirocumab Neutralizes the Pro-inflammatory Risk of Oxidized Phospholipids After Acute Coronary Syndrome

By MedXY 12/25/2025

A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with alirocumab effectively mitigates this risk while significantly reducing biomarker levels.

Cardiology Emergency Medicine news

High-Sensitivity Cardiac Troponin Risk Stratification Safely Accelerates ED Discharge and Improves 1-Year Outcomes

By MedXY 12/24/2025

A secondary analysis of the HiSTORIC trial reveals that using high-sensitivity cardiac troponin for risk stratification significantly reduces ED length of stay and increases safe discharge rates for low- and intermediate-risk patients, with improved 1-year safety outcomes.

Cardiology news

Troponin Assay Transitions: Increased Clinical Burden Without Improved Cardiovascular Outcomes

By MedXY 12/24/2025

Switching from high-sensitivity troponin I to T significantly increases diagnoses of myocardial injury and hospital admissions without improving long-term cardiovascular outcomes, while low-threshold troponin I remains a safe tool for rapid rule-out.

Cardiology Clinical Updates news

Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis

By MedXY 12/18/2025

This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinical practice.

news Public Health Respiratory

Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial

By MedXY 09/27/2025

A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased cardiovascular risk over seven years of follow-up.

Cardiology Clinical Updates news Specialties

Aspirin-Free Strategy in High Bleeding Risk PCI Patients: Insights from STOPDAPT-3 Subgroup Analysis

By MedXY 09/22/2025

In high bleeding risk patients undergoing PCI, aspirin-free prasugrel monotherapy fails to reduce major bleeding and shows increased myocardial infarction risk in ACS but not non-ACS patients, suggesting selective use post-PCI.

Cardiology

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

AI Cardiology Specialties

Advancing Acute Coronary Syndrome Care: ECG-Based Machine Learning Enhances Risk Stratification

By MedXY 08/16/2025

A prospective study shows that machine learning models trained on 12-lead ECG features outperform HEART score in predicting mortality among chest pain patients, improving risk-based care precision.